A new strategy for evaluating antitumor activity in vitro with time-dimensional characteristics of RTCA technology

Fang-Tong LIU; Shu-Yan XING; Jia YANG; Guo-Ying ZHANG; Rong RONG; Xiao-Yun LIU; Dong-Xue YE; Yong YANG; Xiao-Yun LIU; Dong-Xue YE; Rong RONG; Yong YANG; Xiao-Yun LIU; Dong-Xue YE; Yong YANG; Xiao-Yun LIU; Dong-Xue YE; Yong YANG

Return

A new strategy for evaluating antitumor activity in vitro with time-dimensional characteristics of RTCA technology

Author: Fang-Tong LIU ¹ ; Shu-Yan XING ² ; Jia YANG ² ; Guo-Ying ZHANG ² ; Rong RONG ² ; Xiao-Yun LIU ³ ; Dong-Xue YE ³ ; Yong YANG ³ ; Xiao-Yun LIU ⁴ ; Dong-Xue YE ⁴ ; Rong RONG ⁴ ; Yong YANG ⁴ ; Xiao-Yun LIU ⁵ ; Dong-Xue YE ⁵ ; Yong YANG ⁵ ; Xiao-Yun LIU ⁶ ; Dong-Xue YE ⁶ ; Yong YANG ⁶
Author Information

1. Innovative Institute of Chinese, Medicine and Pharmacy
2. College of Pharmacy
3. Experimental Center, Shandong University of Traditional Chinese Medicine
4. Key Laboratory of Classical Theories of TCM, Ministry of Education
5. Shandong Provincial Key Laboratory of Basic Research of Traditional Chinese Medicine
6. Shandong Antiviral Engineering Research Center of Traditional Chinese Medicine
Publication Type:Journal Article
Keywords: antitumor activity; EC50; lung adenocarcinoma; new strategy; RTCA technology; time dimension characteristics
From: Chinese Pharmacological Bulletin 2024;40(3):592-598
CountryChina
Language:Chinese
Abstract: Aim To analyze the anti-A549 and HI299 lung ade-nocarcinoma activities via using examples of baicalin, astragalo-side, hesperidin and cisplatin based on real time cellular analysis (RTCA) technology, and to build a new strategy for EC50 e-valuation reflecting the time-dimensional characteristic. Methods Using RTCA Software Pro for data analysis and GraphPad Prism and Origin Pro plotting, the in vitro anti-A549 and H1299 lung adenocarcinoma activities of baicalin, astragaloside, hesperidin, and cisplatin were characterized using the endpoint method and time dimension, respectively. Results (X) There were significant differences in EC50 values of A549 and H1299 cells at 24 h and 48 h endpoint methods. (2) The correlation coefficient of the curve fitted with the four-parameter equation was > 0. 9, and the dynamic change of EC50 remained relatively stable (the linear fitting of EC50 at adjacent 4 points I slope 1^1) used to calculate the EC50 value within this time dimension. The EC50 of baicalin, astragaloside, hesperidin and cisplatin on A549 cells was 52. 97 ±1.75 плпо! • L~1(16~48 h) , 62.88 ± 2.91 ijunol • L"1 (32.25 -48 h) , 78.84 ±0.33 плпо1 • L"1 (21.5 -29.75 h), 13.57 ±1.54 плпо1 • L_1(27.5 -48 h), respectively; the EC50 of baicalin, astragaloside, hesperidin and cisplatin on H1299 cells was 43. 71 ± 1. 26 |лто1 • L_1 ( 19. 5 -48 h), 47.23 ±1. 19 |лто1 • L_1(14 -48 h) , 39.45 ±0.24 плпо1 • L"1 (12.75 -46.25 h), 25.97 ±4.76 плпо1 • L"1 (10. 25 -48 h) , respectively. The results showed that the time window for the anti-tumor effect of the test solution/drug was different. Conclusions Based on RTCA technology, it is more accurate and reasonable to select EC50 data that exhibit better fitting, stable changes, and time-dimensional characteristics for the evaluation of anti-tumor activity. In addition, this method of distinguishing different effective time of antitumor drugs can provide a reference for the timing of clinical combination drugs, and this approach will also provide a reference for further related studies.